The Benevolent Platform™ drives our three revenue streams. Our business model offers multiple routes for revenue generation and value creation.
Drug discovery offerings
End to End Drug Discovery
-
Platform enables novel discoveries throughout the drug discovery process
-
Continuing to expand on our industry-leading collaborations
-
Validated by collaborations with Astrazeneca and Merck
Platform generated assets
Preclinical & Clinical Development Pipeline
-
5 high potential assets
-
Potentially first-in-class or best-in-class assets providing novel therapeutic opportunities
-
Progressing assets to significant inflection points
New customisable SaaS products
Knowledge Exploration tools
-
Suite of AI products that surface data, perform analysis and give scientific recommendations
-
BenAI-Q and BenAI Research Assistant products enable enhance decisions making
-
Building from our core technologies to develop innovative ways to serve customers and their scientists
LEARN MORE
Reach your full research and development potential.
Speak to our business development team.